Eurofins has launched a new SARS-CoV-2 assay and increased its capacity to detect and monitor new variants of the novel coronavirus.
Initiatives include sequencing more than 5,000 full genomes per day using Artic Next Generation Sequencing (NGS) and debuting NovaType, a SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) assay that identifies the SARS-CoV-2 variants B.1.1.7 and B.1.351.
NovaType is available as a laboratory-developed test (LDT) in Germany and will be rolled out to more than 50 Eurofins laboratories worldwide. The assay is available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programs. It will be available as a research use only (RUO) kit in Europe by the end of January, Eurofins said.
